Tabula Rasa HealthCare has signed a nonbinding Letter of Intent to sell its DoseMeRx solution, according to a Wednesday announcement.
“At our last earnings call, we noted that we were evaluating options to unlock value in noncore assets. This strategic divestiture underscores TRHC’s commitment to sharpening our focus on our core mission, better positioning the company for growth and increased shareholder value,” TRHC Chairman and CEO Calvin H. Knowlton said. “Our search for the right partner to help further advance DoseMe’s innovative solutions has been extensive, and we are encouraged by the interest and enthusiasm in the market for this excellent business and technology.”
DoseMeRx is an advanced precision dosing tool to help physicians and pharmacists accurately dose patients’ high-risk medications based on individual needs, reducing risk and improving patient outcomes.
